First TVB-2640 and enzalutamide for metastatic prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 1 trial tests a new medicine (TVB-2640) combined with enzalutamide in men with prostate cancer that has spread and is no longer responding to hormone treatment. It aims to find a safe dose and see how well the treatment can work against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be over 18 years old and have confirmed prostate cancer seen on lab tests (tissue or fluid sample).
- Have prostate cancer that has spread on scans (bone scan and/or CT/MRI) and is getting worse despite hormone treatment.
- Plan to start enzalutamide now as the first treatment for castration-resistant prostate cancer, or have only had up to one prior medicine like abiraterone or another androgen-blocking drug.
- Be able and willing to get tissue biopsies: one before starting if no recent sample is available, and another from a metastatic spot (or the prostate) about 4–6 weeks after starting both medicines.
- Agree to stay on hormone-suppression shots/tablets (LHRH medicine) if you have not had testicle removal, and use birth control during the study and for 4 months after the last dose.
- Be in good general condition (ECOG 0–1) and have blood/organ test results that are safe based on labs done within 14 days before the first dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a personalized (adaptive) treatment plan versus a steady (continuous) plan using either abiraterone or enzalutamide (with the same standard hormone-suppression). It aims to see which approach controls advanced metastatic prostate cancer better while keeping side effects manageable.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
This trial tests a new drug (TYK-00540) combined with enzalutamide for men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It may be an option if you have tried only one other newer hormone treatment and it failed.
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This study tests a new drug called mevrometostat combined with enzalutamide in men whose prostate cancer has spread and is no longer responding to previous hormone-blocking treatments. The goal is to see if adding mevrometostat helps slow cancer growth when enzalutamide alone is no longer working.
Hear when a new Prostatic Neoplasms, Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.